May 27, 2020
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
Mar 03, 2020
Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors
Jan 27, 2020
Arix Co-founds Quench Bio With Series A Financing
Dec 02, 2019
IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer
Nov 20, 2019
Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
Nov 07, 2019
Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases
Nov 06, 2019
Global Antibody Drug Conjugates Market Report 2019-2030
Oct 29, 2019
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Sep 05, 2019
IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due
Aug 06, 2019
Global Neoantigen Targeted Therapies Market 2019-2030: Marketed and Development Pipeline, Pipeline Analysis, List of Drug Developers
Jul 25, 2019
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
Jun 14, 2019
World Cancer Immunotherapy Market Report 2019 - Outcome Potential / Fast Tracking / Funding / Technology Environment / Target Solutions
May 08, 2019
IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre
May 07, 2019
Science2Startup Symposium Convened Close to 300 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections to Advance Scientific Innovation and Entrepreneurship
Apr 03, 2019
LeadingBiotech's Boston CEO Conference Unites Biopharma Leaders May 28-29 at Four Seasons Hotel
Apr 01, 2019
Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million
Jan 28, 2019
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
Nov 19, 2018
Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform
Nov 13, 2018
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Sep 27, 2018
Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture